2. Search Result
Search Result
Results for "

9903

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

4

Inhibitory Antibodies

1

Natural
Products

2

Recombinant Proteins

1

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9903
    Nivolumab
    Maximum Cited Publications
    21 Publications Verification

    BMS-936558; ONO-4538; MDX-1106

    		 PD-1/PD-L1 Cancer
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab
  • HY-P99259
    Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    		 c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
    Cabiralizumab
  • HY-P99100
    Visugromab
    1 Publications Verification

    CTL-002

    		 TGF-beta/Smad PD-1/PD-L1 Cancer
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Visugromab
  • HY-163028
    ML-T7

    		Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-N9903
    Tetrahydrodehydrodiconiferyl alcohol

    TDDC

    		 Others Others
    Tetrahydrodehydrodiconiferyl alcohol (TDDC) is a reduction product of dihydrodehydrodiconiferyl alcohol catalyzed by phenylcoumaran benzylic ether reductase. Tetrahydrodehydrodiconiferyl alcohol can be isolated from a hydrogenolysis product of protolignin .
    Tetrahydrodehydrodiconiferyl alcohol
  • HY-R02549
    hsa-miR-9903 mimic

    		MicroRNA Cancer
    hsa-miR-9903 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-9903 mimic
    hsa-miR-9903 mimic
  • HY-RI02549
    hsa-miR-9903 inhibitor

    		MicroRNA Cancer
    hsa-miR-9903 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-9903 inhibitor
    hsa-miR-9903 inhibitor
  • HY-R02549A
    hsa-miR-9903 agomir

    		MicroRNA Cancer
    hsa-miR-9903 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-9903 agomir
    hsa-miR-9903 agomir
  • HY-RI02549A
    hsa-miR-9903 antagomir

    		MicroRNA Cancer
    hsa-miR-9903 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-9903 antagomir
    hsa-miR-9903 antagomir
  • HY-P99100A
    Visugromab (Powder)

    CLT-002 (Powder)

    		 TGF-beta/Smad PD-1/PD-L1 Cancer
    Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Visugromab (Powder)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: